|Bid||1,334.00 x 128000|
|Ask||1,335.00 x 209400|
|Day's Range||1,331.00 - 1,370.00|
|52 Week Range||630.00 - 1,980.00|
|Beta (5Y Monthly)||2.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will host a key opinion leader (KOL) meeting on pegunigalsidase alfa, or PRX‑102, the Company's lead drug candidate for the treatment of Fabry Disease, in New York City on Monday, December 2, 2019, at 8:00 a.m. EST.
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 5 cents. The drug developer posted revenue of $10.4 million in the period. The company's shares closed at 44 cents. A year ...